| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
3289-8625 targets the PDZ domain of Dishevelled (Dvl) protein. Dvl is a critical signal transducer in the canonical Wnt/beta-catenin pathway and the non-canonical planar cell polarity pathway. The PDZ domain mediates protein-protein interactions necessary for Dvl function. By blocking this domain, 3289-8625 prevents signal propagation, reducing the stabilization and nuclear translocation of beta-catenin, thereby inhibiting the transcription of pro-proliferative target genes.
|
|---|---|
| ln Vitro |
3289-8625 binds to the Dvl PDZ domain with a Kd of 10.6 microM. It inhibits Wnt signaling in cell-based assays. In prostate cancer PC-3 cells, it slows cell growth with an IC50 of 12.5 microM. Mechanistically, it reduces the levels of beta-catenin in both the cytosolic and membrane fractions of PC-3 cells, leading to suppression of cell proliferation and induction of effects on embryonic development pathways.
|
| ln Vivo |
In vivo, 3289-8625 can be used to study the role of Wnt signaling in embryonic development. Blockade of Dvl disrupts normal axis formation in early embryos. It also suppresses tumor growth in prostate cancer xenograft models, as reducing beta-catenin levels correlates with reduced tumor progression and metastasis. Specific in vivo dosing data (e.g., administration route, mg/kg) is not provided in the summary.
|
| Enzyme Assay |
Standard PDZ domain binding assay (Fluorescence Polarization). A fluorescently labeled peptide ligand known to bind the Dvl PDZ domain (e.g., FITC-WGKDYW) is used. The PDZ domain protein (recombinant) is mixed with the fluorescent peptide (1-10 nM) in assay buffer (PBS, pH 7.4, 0.005% Tween 20). 3289-8625 (0.1-1000 uM) is added. After equilibration, FP (mP) is measured. The IC50 is calculated, and the Kd is derived (10.6 uM). Standard Wnt/beta-catenin reporter assay (TCF/LEF Luciferase). HEK293T cells are transfected with a SuperTOPFlash (STF) luciferase reporter (driven by TCF/LEF response elements). Cells are seeded in 96-well plates. After 24 hours, cells are treated with 3289-8625 (1-100 uM) in the presence or absence of Wnt3a conditioned media. After 24 hours, luciferase activity is measured using a Bright-Glo assay. The IC50 for inhibition of Wnt signaling is calculated. beta-catenin levels are measured by Western blot.
|
| Animal Protocol |
Xenograft mouse model for prostate cancer. Female BALB/c nude mice are injected subcutaneously with PC-3 cells (5×10⁶). When tumors reach ~150 mm3, mice are randomized into groups (n=8). 3289-8625 is administered intraperitoneally (50-100 mg/kg) or orally daily for 28 days. Tumor volume is measured twice weekly. At sacrifice, tumors are harvested for immunohistochemistry to assess beta-catenin localization and Ki-67 (proliferation index). This demonstrates in vivo suppression of Wnt signaling.
|
| ADME/Pharmacokinetics |
Not applicable. As a small-molecule inhibitor, the PK of 3289-8625 has not been fully characterized in published abstracts. It is a solid powder, soluble in DMSO (125 mg/mL). For in vivo use, it would be formulated in a vehicle such as 10% DMSO, 40% PEG300, 5% Tween-80, 45% saline for IP injection. The t½, Cmax, and oral bioavailability are not reported.
|
| Toxicity/Toxicokinetics |
No specific toxicity data is reported. It is a Wnt signaling inhibitor and has an IC50 of 12.5 microM in PC-3 cells, indicating it is cytostatic or cytotoxic at that concentration. Off-target effects on normal stem cells (which rely on Wnt for proliferation) could be a concern, but no toxicity data in animals is listed. Standard chemical safety: Wear PPE, avoid inhalation.
|
| References | |
| Additional Infomation |
2-[[3-[(2-phenylacetyl)amino]benzoyl]amino]benzoic Acid is a member of the benzamide class of compounds.
3289-8625 is also known as Dvl-PDZ Domain Inhibitor II and 2-[3-(2-Phenylacetamido)benzamido]benzoic acid. Its molecular formula is C22H1₈N2O4, MW 374.39. It is a potent chemical probe for studying the specific protein-protein interactions of the Dishevelled PDZ domain, a difficult-to-target protein interaction surface. For research use only, not for human therapeutic use. |
| Molecular Formula |
C22H18N2O4
|
|---|---|
| Molecular Weight |
374.39
|
| Exact Mass |
374.127
|
| CAS # |
294891-81-9
|
| PubChem CID |
5221450
|
| Appearance |
Solid powder
|
| LogP |
4.852
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
28
|
| Complexity |
559
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(C=C1)CC(=O)NC2=CC=CC(=C2)C(=O)NC3=CC=CC=C3C(=O)O
|
| InChi Key |
OBGIRQUECFHUEY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H18N2O4/c25-20(13-15-7-2-1-3-8-15)23-17-10-6-9-16(14-17)21(26)24-19-12-5-4-11-18(19)22(27)28/h1-12,14H,13H2,(H,23,25)(H,24,26)(H,27,28)
|
| Chemical Name |
2-[[3-[(2-phenylacetyl)amino]benzoyl]amino]benzoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~333.88 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6710 mL | 13.3551 mL | 26.7101 mL | |
| 5 mM | 0.5342 mL | 2.6710 mL | 5.3420 mL | |
| 10 mM | 0.2671 mL | 1.3355 mL | 2.6710 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
